Pharma

Your Article Summary

See Latest Articles

AVI BioPharma to Present Safety Update from Ongoing Systemic Trial of AVI-4658 at 7th Annual Action Duchenne International Conference
AVI BioPharma, 10/23/09

AVI BioPharma, Inc., a developer of RNA–based drugs, announced that it will present updated preliminary safety data from its ongoing systemic Phase 1b/2 clinical trial of AVI–4658 in patients with Duchenne muscular dystrophy at the 7th Annual Action Duchenne Conference taking place Oct. in London, UK.

Today in Conferences/Meetings...keeping you current

Receive free subspecialty "5-minute updates" via email

Quality of trials reported as conference abstracts in China: How well are they reported
International Journal of Technology Assessment in Health Care, 11/05/09

User Groups Prove Helpful
HealthDataManagement, 11/03/09

Salix Pharmaceuticals Reviews American Association For The Study Of Liver Diseases Annual Meeting
Salix Pharmaceuticals, 11/03/09

See All of Conferences/Meetings